The Lund-based company was one of only thirty-five selected from 453 applicants in the EIC’s latest evaluation round. The EIC Fund investment would come as part of an upcoming financing round.

“This grant caps a fantastic year for Asgard, in which we have made huge progress on the road to becoming a clinical-stage company. It will help us prepare AT-108 quicker, so we are ready for the clinic and can start dosing patients next year,” says Cristiana Pires, co-founder and CEO of Asgard Therapeutics.

AT-108 is a first-in-class, off-the-shelf immunotherapy. It reprograms cells inside the tumor into antigen-presenting, dendritic-like cells known as cDC1-like cells, which trigger a personalized anti-tumor immune response. Its initial indications are head and neck squamous cell carcinoma and microsatellite-stable colorectal cancer.

Earlier this month, Asgard published a study in Immunity showing that its approach can induce tertiary lymphoid structures, which help fight cancer, in both cold and hot tumor types. At this year’s annual meeting of the Society for Immunotherapy of Cancer (SITC), it also presented a framework of translational biomarkers for AT-108. In May, preclinical data showed that AT-108 on its own doubled median survival in animal models that did not respond to checkpoint inhibitors.